down arrow

Anixa Biosciences, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US03528H1095
USD
4.74
0.54 (12.86%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

4.644.85

52 Week

2.074.98
Valuation
Technical
Day's Volume

CASH

202.48 k

Shareholding (Apr 2025)

FII

1.04%

Held by 13 FIIs

DII

92.96%

Held by 7 DIIs

Promoter

0.00%

How big is Anixa Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Anixa Biosciences, Inc. has a market capitalization of 118.54 million and reported net sales of 0.00 million with a net profit of -12.24 million over the last four quarters. As of Oct 24, the company has shareholder's funds of 20.00 million and total assets of 21.59 million.

As of Jun 18, Anixa Biosciences, Inc. has a market capitalization of 118.54 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -12.24 million during the same period.<BR><BR>As of Oct 24, the reporting period shows shareholder's funds of 20.00 million and total assets amounting to 21.59 million.

Read More

What does Anixa Biosciences, Inc. do?

22-Jun-2025

Anixa Biosciences, Inc. is a biotechnology company focused on cancer immunotherapy and diagnostics. As of April 2025, it has a market cap of $118.54 million and reported a quarterly net profit loss of $3 million.

Overview: <BR>Anixa Biosciences, Inc. is a biotechnology company focused on developing cancer immunotherapy and diagnostic platforms within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Net Profit: -3 Million (Quarterly Results - Apr 2025) <BR>Market cap: USD 118.54 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.97 <BR>Return on Equity: -76.26% <BR>Price to Book: 7.38<BR><BR>Contact Details: <BR>Address: 3150 Almaden Expy Ste 250, SAN JOSE CA: 95118 <BR>Tel: 1 408 7089808 <BR>Fax: 1 302 6555049 <BR>Website: https://www.anixa.com/

Read More

Who are in the management team of Anixa Biosciences, Inc.?

22-Jun-2025

As of March 2022, Anixa Biosciences, Inc.'s management team includes Dr. Amit Kumar as Chairman, President, and CEO, with Mr. Lewis Titterton as Lead Independent Director and Dr. Arnold Baskies, Mr. David Cavalier, Ms. Emily Gottschalk, and Dr. John Monahan as Independent Directors.

As of March 2022, the management team of Anixa Biosciences, Inc. includes Dr. Amit Kumar, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features Mr. Lewis Titterton as the Lead Independent Director, along with Dr. Arnold Baskies, Mr. David Cavalier, Ms. Emily Gottschalk, and Dr. John Monahan, all of whom are Independent Directors.

Read More

Is Anixa Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Anixa Biosciences, Inc. shows a neutral trend with mixed indicators, outperforming the S&P 500 in the short term but underperforming over the past year, suggesting a cautious investment approach.

As of 11 September 2025, the technical trend for Anixa Biosciences, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed indicators influencing this position. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish. The daily moving averages are bullish, but the weekly KST and OBV are both mildly bearish. Bollinger Bands indicate bullishness on both weekly and monthly time frames. <BR><BR>In terms of returns, Anixa has outperformed the S&P 500 over the past week (14.24% vs. 1.05%) and month (13.09% vs. 2.33%), but it has underperformed over the longer term, with a 1-year return of -2.32% compared to the S&P 500's 17.14%. Overall, the mixed signals suggest a cautious approach.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 96 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.97

stock-summary
Return on Equity

-76.26%

stock-summary
Price to Book

5.97

Revenue and Profits:
Net Sales:
(Quarterly Results - Apr 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
58.53%
0%
58.53%
6 Months
68.09%
0%
68.09%
1 Year
42.77%
0%
42.77%
2 Years
44.95%
0%
44.95%
3 Years
-3.07%
0%
-3.07%
4 Years
53.4%
0%
53.4%
5 Years
68.68%
0%
68.68%

Anixa Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Anixa Biosciences, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for Anixa Biosciences, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed indicators influencing this position. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish. The daily moving averages are bullish, but the weekly KST and OBV are both mildly bearish. Bollinger Bands indicate bullishness on both weekly and monthly time frames. In terms of returns, Anixa has outperformed the S&P 500 over the past week (14.24% vs. 1.05%) and month (13.09% vs. 2.33%), but it has underperformed over the longer term, with a 1-year return of -2.32% compared to the S&P 500's 17.14%. Overall, the mixed signals suggest a cautious approach....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-8.75%
EBIT to Interest (avg)
-12.63
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.97
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
19.69%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.53
EV to EBIT
-5.58
EV to EBITDA
-5.59
EV to Capital Employed
73.34
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1314.40%
ROE (Latest)
-76.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Apr 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 6 Schemes (6.0%)

Foreign Institutions

Held by 13 Foreign Institutions (1.04%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Apr'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Apr 2025 is 0.00% vs 0.00% in Jan 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Apr 2025 is 12.50% vs -10.34% in Jan 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Jan'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.00",
          "val2": "-3.40",
          "chgp": "11.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.80",
          "val2": "-3.20",
          "chgp": "12.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Oct'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Oct 2024 is -100.00% vs 0.00% in Oct 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Oct 2024 is -28.28% vs 28.26% in Oct 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Oct'24",
        "Oct'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.80",
          "val2": "-11.00",
          "chgp": "-25.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-12.70",
          "val2": "-9.90",
          "chgp": "-28.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-52,433.30%",
          "chgp": "5,243.33%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Apr'25 - QoQstock-summary
Apr'25
Jan'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-3.00
-3.40
11.76%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.80
-3.20
12.50%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Apr 2025 is 0.00% vs 0.00% in Jan 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Apr 2025 is 12.50% vs -10.34% in Jan 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Oct'24stock-summary
Oct'24
Oct'23
Change(%)
Net Sales
0.00
0.20
-100.00%
Operating Profit (PBDIT) excl Other Income
-13.80
-11.00
-25.45%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-12.70
-9.90
-28.28%
Operating Profit Margin (Excl OI)
0.00%
-52,433.30%
5,243.33%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Oct 2024 is -100.00% vs 0.00% in Oct 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Oct 2024 is -28.28% vs 28.26% in Oct 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Anixa Biosciences, Inc. stock-summary
stock-summary
Anixa Biosciences, Inc.
Pharmaceuticals & Biotechnology
Anixa Biosciences, Inc. is a biotechnology company. The Company is developing a cancer immunotherapy program, which leverages chimeric endocrine receptor t-cell (CER-T) technology, and is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek liquid biopsy technology is a series of non-invasive blood tests for early detection of solid tumors based on the body's immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream. This technology enables cancer detection in its earliest stages in efforts to treat patients when the disease is curable. The Company has developed techniques and protocols for measuring the subtle immunological changes that occur in the blood stream during tumor development. Through its protocols, the Company has detected the biomarkers in the peripheral blood of biopsy verified cancer patients.
Company Coordinates stock-summary
Company Details
3150 Almaden Expy Ste 250 , SAN JOSE CA : 95118
stock-summary
Tel: 1 408 70898081 408 7089808
stock-summary
https://www.anixa.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."